{"filings":[{"id":746477,"accession_number":"0001628280-26-039147","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2026-05-29T20:05:00+00:00","items":["5.02"],"status":"ready","headline":"Director Anne O'Riordan not standing for re-election at Jazz's 2026 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Class III director Anne O'Riordan will not seek re-election at the 2026 annual meeting, continuing board refreshment.","O'Riordan's decision was not due to any dispute or disagreement with the company or board.","Board will continue to evaluate composition; no immediate replacement announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91772,"accession_number":"0001232524-26-000024","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jazz Pharma Q1 revenue $1.1B (+19% YoY), EPS $4.43 GAAP / $6.34 adj; Zanidatamab PDUFA Aug 25","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $1.1B (+19% YoY); GAAP EPS $4.43, non-GAAP adj. EPS $6.34; operating cash flow $408M.","Xywav net product sales $408M (+18% YoY) with 425 net patient adds; Epidiolex grew 15% YoY.","Zanidatamab sBLA for HER2+ 1L GEA granted Priority Review; PDUFA date Aug 25, 2026.","Company reaffirms 2026 revenue and expense guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":4.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":1068900000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102091,"accession_number":"0001232524-26-000012","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jazz Pharma FY2025 revenue $4.3B (+5% YoY); GAAP net loss $356M vs $560M income in 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues record $4.3B in FY2025 (+5% YoY); Q4 revenue $1.2B (+10% YoY).","GAAP net loss $356M ($5.84 diluted loss per share) vs prior year income of $560M ($8.65 EPS).","Non-GAAP adjusted net income $522M ($8.38 EPS) vs $1.35B ($20.65 EPS) in 2024; adjusted down significantly.","Xywav $1.7B (+12%), Epidiolex $1.1B (+9%) in 2025; Modeyso launch generated $48M.","2026 revenue guidance $4.25-$4.50B; sBLA submission for zanidatamab in GEA expected in 1Q26."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":4267586000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102090,"accession_number":"0001193125-26-009899","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jazz Pharma reaffirms FY2025 total revenue guidance at JPM conference","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Expects to meet previously announced total revenue guidance range for FY2025 year ended Dec 31, 2025.","Provided revenue expectations for Xywav, Epidiolex, and Modeyso for the full year 2025.","Presentation delivered at 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118425,"accession_number":"0001193125-25-283887","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Positive Phase 3 results for Ziihera: significant PFS/OS improvement in first-line HER2+ GEA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ziihera + chemo showed statistically significant PFS improvement vs trastuzumab + chemo; OS clinically meaningful trend at first interim analysis.","Ziihera + tislelizumab + chemo showed statistically significant OS and PFS improvements vs control.","Benefit observed in both PD-L1 positive and negative subgroups; improvements in ORR and DoR.","Company plans to submit sBLA in first half of 2026; data to be presented at medical meeting Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118424,"accession_number":"0001232524-25-000073","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jazz Pharma Q3 rev $1.13B (+7%), GAAP EPS $4.08, adj. EPS $8.13; FY25 rev guid narrowed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $1.126B (+7% YoY); GAAP net income $251M, non-GAAP adj. net income $501M.","Epidiolex sales grew 20% to $302.6M; Xywav sales grew 11% to $431.4M; Modeyso launch contributed $11.0M.","Zepzelca + atezolizumab combo approved for 1L maintenance ES-SCLC; NCCN inclusion.","Saniona licensing agreement for SAN2355, a Kv7.2/7.3 activator for epilepsy and other indications.","FY2025 total revenue guidance narrowed to $4.175-$4.275B from $4.150-$4.300B."],"consensus_eps_estimate":null,"consensus_eps_actual":-9.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":3069660000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118423,"accession_number":"0001628280-25-046763","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Jazz Pharma appoints Dr. Ted Love to board; director Kenneth O'Keefe to retire Dec 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Ted Love appointed as Class I director effective Dec 1, 2025, term expiring at 2027 AGM.","Love will serve on Audit and Science & Medicine Committees under standard non-employee director compensation.","Director Kenneth O'Keefe retires from Board effective Dec 1, 2025, with no dispute or disagreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118422,"accession_number":"0001193125-25-245815","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Jazz settles patent litigation with Avadel; grants Lumryz license, pays $90M","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Jazz pays $90M lump sum to Avadel and waives certain prior royalties to settle all litigation.","Avadel gets immediate license for Lumryz in narcolepsy; license for other indications starts March 1, 2028.","Avadel will pay 3.85% royalty on narcolepsy Lumryz sales (starting Oct 1, 2025) and 10% on other indications.","Jazz expects ~$90M pre-tax charge in Q3 2025, funded with cash on hand.","Jazz denies all alleged wrongdoing; both parties dismiss pending legal proceedings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134860,"accession_number":"0001232524-25-000061","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jazz Q2 GAAP net loss $718M; revenue $1.05B up 2%; updates FY25 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenues $1.05B, up 2% YoY; GAAP net loss $718.5M vs $168.6M profit in Q2 2024.","Non-GAAP adjusted net loss $504.8M vs $360.7M income; FY2025 revenue guidance revised to $4.15-$4.30B.","Xywav revenue +13% to $415.3M; added ~625 net patients in Q2, active patients ~15,225.","Renee Gala named President and CEO effective Aug 11; Bruce Cozadd becomes Chairman.","FDA Priority Review for Zepzelca combo in 1L ES-SCLC (PDUFA Oct 7); dordaviprone PDUFA Aug 18."],"consensus_eps_estimate":null,"consensus_eps_actual":-13.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":1943553000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134859,"accession_number":"0001232524-25-000051","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Jazz Pharma shareholders elect four directors and ratify KPMG as auditor at 2025 AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All four director nominees were elected: Cook, Enright, Mulligan, Riedel, each with >46M votes for.","KPMG ratified as independent auditor for FY2025 with 54.8M for, 0.99M against (no broker non-votes).","Say-on-pay advisory vote approved: 48.3M for, 2.9M against, 193,593 abstentions.","Board granted authority to issue ordinary shares for cash without pre-emption rights: 53.6M for, 2.2M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134858,"accession_number":"0001193125-25-157388","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Jazz Pharma appoints Renee Gala as President & CEO, effective Aug 11, 2025; Cozadd remains Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Renee Gala, previously President & COO, becomes President & CEO effective August 11, 2025, and joins the Board.","Bruce Cozadd retires as CEO on Aug 11, transitions to advisor through Sep 12, then remains Chairperson.","Gala's base salary increases to $1.2M (from $900k); target bonus rises to 110% of salary (from 80%).","Gala receives a one-time promotion equity grant of ~$6.5M (33% RSUs, 67% PSUs) on top of $6M annual grant.","Severance enhanced: lump sum of 150% base salary (was 100%) and COBRA coverage extended to 18 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151797,"accession_number":"0001232524-25-000025","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jazz Q1 revenues flat at $898M; GAAP net loss widens to $92.5M; updated guidance after Chimerix","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $92.5M ($1.52 loss/share) vs $14.6M loss in 1Q24; adjusted net income $105.2M ($1.68 EPS) vs $178.4M ($2.63).","Xywav revenue $344.8M (+9% YoY), Epidiolex $217.7M (+10% YoY); Xyrem fell 42% to $37.2M.","Affirmed 2025 total revenue guidance $4.15-4.40B; updated to reflect Chimerix acquisition and Xyrem settlements.","Completed Chimerix acquisition in April; added dordaviprone; PDUFA Aug 18, 2025 for recurrent H3 K27M-mutant glioma.","Submitted sNDA for Zepzelca in 1L ES-SCLC maintenance; positive CHMP opinion for zanidatamab in 2L BTC."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":897841000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151796,"accession_number":"0001193125-25-087233","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2025-04-21T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Jazz completes $935M acquisition of Chimerix, adds dordaviprone to pipeline","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition completed for ~$935M cash; $8.55 per share.","Dordaviprone for H3 K27M-mutant diffuse glioma under FDA Priority Review; PDUFA date Aug 18, 2025.","If approved, could be first FDA-approved therapy for that indication; potential near-term opportunity.","Also in Phase 3 ACTION trial for newly diagnosed, non-recurrent diffuse glioma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151795,"accession_number":"0001193125-25-075871","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Jazz Pharma to pay $145M to settle Xyrem antitrust class action; records Q1 charge","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Jazz Pharmaceuticals Ireland subsidiary agrees to pay $145M lump sum to settle indirect Xyrem purchaser class action.","Company will record a pre-tax charge of approximately $145M in Q1 2025, funded by cash on hand.","Settlement remains subject to court approval; Jazz denies all alleged wrongdoing.","The settlement resolves the majority of claims in the multi-district litigation; additional settlements with remaining plaintiffs may be significant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170661,"accession_number":"0001193125-25-046226","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Jazz Pharma to acquire Chimerix for ~$935M ($8.55/sh), adding brain-tumor drug dordaviprone","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["All-cash tender offer at $8.55/sh; represents ~72% premium over Chimerix's March 4 close.","Chimerix's dordaviprone (NDA under Priority Review, PDUFA Aug 18, 2025) targets H3 K27M-mutant diffuse glioma.","If approved, dordaviprone could be first FDA-approved therapy for this rare brain tumor; eligible for Rare Pediatric Disease PRV.","Jazz expects to fund deal from existing cash; transaction projected to close in Q2 2025.","Chimerix board unanimously recommends shareholders tender shares; patent protection into 2037 with potential extension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.88,"calibrated_materiality_score":0.88,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170658,"accession_number":"0001193125-25-047189","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K/A","filed_at":"2025-03-05T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Jazz Pharmaceuticals to acquire Chimerix for $8.55/share in all-cash tender offer","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Tender offer to commence by March 24, 2025; Chimerix board unanimously recommends.","Offer subject to minimum tender condition, HSR clearance, and no material adverse effect.","After tender, merger under DGCL Section 251(h); remaining shares converted at same $8.55.","Amendment No. 1 corrects typographical error in exhibit; no substantive changes to terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170660,"accession_number":"0001232524-25-000009","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jazz Pharma reports record 2024 revenue $4.1B; guides 2025 rev $4.15-4.40B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record total revenue $4.07B for FY2024, up 6% YoY; Q4 revenue $1.09B, up 8% YoY.","GAAP diluted EPS $8.65 (FY2024) vs $6.10 (FY2023); Non-GAAP diluted EPS $20.90 vs $18.29.","Xywav+Epidiolex grew 16% and 15% YoY; oncology revenue surpassed $1.1B (+9%).","2025 guidance: total revenue $4.15-4.40B; GAAP EPS $9.15-11.50; Non-GAAP EPS $22.50-24.00.","Cash from ops $1.4B; voluntary $750M debt prepayment in Jan 2025; Ziihera launch initial sales $1.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":8.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":4068950000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170659,"accession_number":"0001193125-25-004989","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jazz Pharma confirms FY2024 revenue guidance met at J.P. Morgan conference","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company expects to meet previously announced total, neuroscience and oncology revenue guidance for year ended Dec 31, 2024.","Outlook disclosed at J.P. Morgan Healthcare Conference on Jan 14, 2025.","No specific revenue or EPS figures provided; guidance ranges unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187640,"accession_number":"0001193125-24-279656","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Jazz CEO Bruce Cozadd to retire by end of 2025; company to search for successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bruce Cozadd notified Board of intent to retire as CEO upon appointment of successor.","Formal search process will consider both internal and external candidates for CEO.","After retiring as CEO, Cozadd will continue to serve as Chairperson of the Board.","Cozadd remains CEO until successor is appointed; transition expected by end of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187639,"accession_number":"0001193125-24-266184","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Jazz Pharmaceuticals expands revolver to $885M, extends maturity to 2029","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Revolving credit facility increased from $500M to $885M; maturity extended from May 2026 to Nov 2029.","Initial applicable margin reduced by 125 bps: Term SOFR +2.00% and prime +1.00%.","Facility was undrawn as of Nov 26, 2024; financial covenants apply only when drawn.","Springing maturity provisions tied to 2026 exchangeable notes and 2028 term loan thresholds.","Amendment adds new lenders and commits to customary conditions for effectiveness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187638,"accession_number":"0001193125-24-262940","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Jazz Pharmaceuticals receives FDA accelerated approval for Ziihera in HER2+ biliary tract cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved Ziihera (zanidatamab-hrii) for adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) BTC.","Approval based on 52% objective response rate and median duration of response of 14.9 months by independent central review.","First and only dual HER2-targeted bispecific antibody approved for this indication in the U.S.","Continued approval contingent on confirmatory Phase 3 trial HERIZON-BTC-302; Boxed Warning for embryo-fetal toxicity.","Investor webcast scheduled for December 11, 2024, to discuss clinical data and commercialization strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187637,"accession_number":"0001232524-24-000084","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jazz Q3 revenue tops $1.05B, raises EPS guidance, affirms 2024 revenue outlook at $4.0-4.1B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2024 record revenue >$1.05B; key growth drivers (Xywav, Epidiolex, Rylaze) up 14% YoY.","Total 2024 revenue guidance reaffirmed at $4.0-4.1B; oncology revenue guidance lowered to $1.08-1.13B.","GAAP EPS guidance raised to $6.70-8.50; non-GAAP EPS guidance raised to $19.50-20.60.","Xywav added ~400 net patients in Q3; strong sleep performance continues.","Zanidatamab PDUFA Nov 29 for 2L BTC; sNDA for Zepzelca in 1L ES-SCLC planned 1H25."],"consensus_eps_estimate":null,"consensus_eps_actual":5.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":2980777000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187636,"accession_number":"0001232524-24-000073","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2024-10-16T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Jazz Pharma ends Palo Alto lease early, signs new lease nearby","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Existing lease at 3170 Porter Drive terminated effective June 30, 2025 (original expiry Oct 2029).","Landlord secured replacement tenant; Jazz will pay a lease modification payment.","New lease executed Oct 11, 2024 for 3000 El Camino Real, Palo Alto; occupancy by July 1, 2025.","Jazz continues U.S. operations in Palo Alto, Carlsbad, CA and Philadelphia, PA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204123,"accession_number":"0001193125-24-215168","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2024-09-06T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Jazz Prices $1B 3.125% Exchangeable Notes Due 2030, Preps $500M Loan Repayment & $150M Buyback","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$1.0B aggregate principal of 3.125% exchangeable senior notes due 2030, including $150M overallotment exercised.","Initial exchange price ~$153.05 per share, a ~40% premium over Sept 3 closing price of $109.32.","Net proceeds ~$981M; ~$500M to prepay term loans under credit agreement, remainder for general corporate.","Concurrent $150M share repurchase from note purchasers at $109.32/share, reducing remaining buyback authority.","Transaction closed Sept 6, 2024; notes guaranteed by Jazz on senior unsecured basis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204122,"accession_number":"0001193125-24-208688","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2024-08-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Jazz Pharma wins partial injunction against Avadel's Lumryz, ongoing royalty above 3.5%","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["On August 27, 2024, U.S. District Court granted Jazz's motion for permanent injunction against Avadel.","Injunction prevents Avadel from seeking FDA approval or marketing Lumryz for idiopathic hypersomnia or other new indications.","Avadel is enjoined from infringing Claim 24 of Jazz's '782 patent through February 2036, except for narcolepsy and existing patients.","Court awarded Jazz an ongoing royalty for future narcolepsy Lumryz sales at a rate to be determined above 3.5%.","Jazz previously won jury verdict finding '782 patent valid and damages for past Lumryz sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204121,"accession_number":"0001232524-24-000065","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jazz Q2 revenue >$1B record; key drugs up 13-22%; guides EPS higher","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Xywav sales +13%, Epidiolex +22%, Rylaze +6% YoY; oncology revenue +10% YoY.","Zanidatamab granted Priority Review; PDUFA Nov 29, 2024 for 2L BTC.","Narrowed 2024 total revenue guidance to $4.0-$4.1B; lowered oncology outlook to $1.10-$1.15B.","GAAP EPS guidance raised to $6.00-$8.00; non-GAAP EPS to $19.20-$20.30.","GAAP net income affirmed $385-$530M; non-GAAP adjusted net income $1.275-$1.350B."],"consensus_eps_estimate":null,"consensus_eps_actual":2.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":1925808000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204120,"accession_number":"0001232524-24-000056","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2024-07-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Jazz Pharma shareholders elect directors, ratify auditor, approve say-on-pay at 2024 AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All four director nominees elected (Hamill, Kennedy, O'Keefe, Smith) with 50.5M-52.8M votes for.","Ratification of KPMG as auditor for FY2024 approved (56.7M for, 1.2M against).","Advisory say-on-pay passed (49.3M for, 4.8M against); one-year frequency preferred (52.7M).","Authority to issue ordinary shares for cash without pre-emption rights approved (52.6M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204119,"accession_number":"0001193125-24-181938","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2024-07-22T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Jazz reprices $2.7B term loan; margin cut 75 bps to 2.25%+SOFR","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered Amendment No. 2 to Credit Agreement; Tranche B-2 Dollar Term Loans replace Tranche B-1 at same $2,707,000,000 outstanding.","Interest margin reduced 75 basis points: new rates are 2.25% (Term SOFR) and 1.25% (prime) vs prior margins.","Maturity unchanged at May 5, 2028; quarterly amortization of 0.2863% of initial principal; SOFR floor of 0.50% remains.","Proceeds from new $289.6M additional borrowing used to repay non-converted Tranche B-1 loans; structure includes converting and non-converting lenders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220844,"accession_number":"0001193125-24-151941","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Catherine Sohn to retire, not standing for re-election at 2024 AGM","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Catherine Sohn, Pharm.D. notified board of retirement effective at 2024 annual general meeting.","Decision not due to any dispute or disagreement with company or board on operations, policies, or practices.","No replacement or nominee announced for the departing director position."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220843,"accession_number":"0001232524-24-000031","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jazz Pharma Q1 GAAP net loss $14.6M, non-GAAP EPS $2.68; affirms FY24 revenue guidance $4.0-4.2B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $902M (+1% YoY); GAAP net loss $14.6M ($0.23 loss/diluted) vs net income $69.4M ($1.04/diluted) in 1Q23.","Non-GAAP adjusted net income $182.2M ($2.68 EPS) down from $285.3M ($3.95 EPS); cost increases in SG&A and R&D.","Key growth drivers: Xywav +14%, Epidiolex +5%, Rylaze +20% YoY; Xyrem fell 64% to $64.2M.","Oncology revenues +13% to $257.5M; zanidatamab BLA for 2L BTC submitted; Phase 2b suvecaltamide data expected late 1H24.","FY24 guidance affirmed: total revenue $4.0-4.2B, non-GAAP gross margin ~93%, non-GAAP EPS $18.15-19.35."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":901983000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240444,"accession_number":"0001232524-24-000014","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jazz Pharma FY23 net income $414.8M vs loss; guides FY24 rev $4.0-4.2B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $3.84B in 2023, up 5% YoY; Q4 revenue $1.01B, up 4% YoY.","GAAP EPS $6.10; non-GAAP adjusted EPS $18.29, vs. $13.20 in 2022.","Key growth drivers: Xywav +33%, Epidiolex +15%, Rylaze +40% in 2023.","2024 guidance: revenue $4.0-4.2B, non-GAAP adjusted EPS $18.15-19.35.","Oncology revenue surpassed $1B in 2023; $161M remains for share buybacks."],"consensus_eps_estimate":null,"consensus_eps_actual":6.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":3834204000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240443,"accession_number":"0001193125-24-047087","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Jazz Pharmaceuticals appoints Patrick Kennedy to Board; Peter Gray not standing for re-election","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Patrick Kennedy appointed as Class I director effective March 1, 2024; term expires at 2024 AGM.","Kennedy will serve on the Audit Committee; receives standard non-employee director compensation.","Peter Gray notified the Board he will not stand for re-election at the 2024 Annual Meeting, with no disagreement with the Company.","Kennedy entered into Jazz's standard indemnification agreement for directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240442,"accession_number":"0001193125-24-040726","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Jazz Pharmaceuticals names Philip Johnson as CFO, effective March 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Philip Johnson appointed EVP and CFO; succeeds Renée Galá who became President and COO in October 2023.","Johnson previously served as Group VP of Finance, Treasurer at Eli Lilly; over 35 years financial experience.","Annual base salary $700,000; target bonus 65% of salary; signing bonus $150,000.","New hire equity grant approximate value $4M, equal mix of restricted stock units and performance stock units."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240441,"accession_number":"0001193125-24-015517","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2024-01-25T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Jazz reprices $2.72B term loans; margin cut 50 bps to Term SOFR+3.00%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Existing $2.7225B Initial Dollar Term Loans refinanced into same principal of Tranche B-1 Dollar Term Loans.","New margin set at Term SOFR+3.00% (prime+2.00%), down from SOFR+3.50%; Term SOFR floor 0.50%.","Additional $201.9M borrowed to repay Initial Dollar Term Loans that were not converted.","Maturity unchanged at May 5, 2028; quarterly amortization at 0.2847% of initial principal.","Repricing effective January 19, 2024; no change to covenants or security package."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240440,"accession_number":"0001193125-24-003910","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jazz Pharma reaffirms 2023 revenue guidance; sees 2024 double-digit growth for key drugs","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Reaffirms 2023 total, neuroscience, and oncology revenue guidance range.","Xywav, Epidiolex, and Rylaze expected to have combined double-digit revenue growth in 2024.","High-sodium oxybate authorized generic royalty revenue expected to grow in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":6.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":3834204000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257960,"accession_number":"0001193125-23-295943","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2023-12-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Jazz Pharmaceuticals EVP & GM US Kim Sablich to depart Dec 31, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kim Sablich, EVP and General Manager, US, will depart the company effective December 31, 2023.","She will no longer serve as an executive officer of Jazz Pharmaceuticals.","No successor has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257959,"accession_number":"0001232524-23-000051","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jazz Pharmaceuticals Reports Q3 2023 Revenue of $972M, Raises Full-Year Guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Xywav net product sales grew 30% year-over-year to $331.6M; total oxybate revenue annualizing at $1.9B","Epidiolex net product sales up 9% to $213.7M; Rylaze up 43% to $104.9M","Company raises 2023 total revenue guidance to $3.75-$3.875B and oncology guidance to $975M-$1.05B","Plan to initiate zanidatamab rolling BLA submission this year for accelerated approval in 2L biliary tract cancers","GAAP net income of $146.8M vs. loss of $19.6M in Q3 2022; non-GAAP adjusted net income $340.1M"],"consensus_eps_estimate":null,"consensus_eps_actual":4.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":2822269000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275282,"accession_number":"0001193125-23-233019","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2023-09-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Jazz Pharma President & COO Swisher to retire; CFO Galá promoted to COO; interim CFO named","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Daniel Swisher Jr., President & COO, to retire effective Mar 31, 2024; duties cease Oct 1, 2023.","Renée Galá, former EVP & CFO, appointed President & COO effective Oct 1, 2023.","Galá's base salary raised to $800K (from $735K), target bonus 75% (from 60%), plus $200K one-time equity.","Patricia Carr, SVP & Chief Accounting Officer, named interim principal financial officer while CFO search underway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275281,"accession_number":"0001232524-23-000036","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jazz Pharma Q2 revenue $957M (+3% YoY); GAAP EPS $1.52 beats; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $957M (+3% YoY); GAAP net income $104.4M ($1.52 diluted EPS) vs $34.7M ($0.55) prior year.","Xywav sales $326.6M (+39% YoY); Epidiolex $202.2M (+15%); Rylaze $101.7M (+39%).","Raises FY2023 guidance: revenue $3.725-$3.875B; non-GAAP adjusted EPS raised to $18.15-$19.00 from $16.90-$17.85.","Repurchased $100M in shares under $1.5B program; $336M remaining as of June 30, 2023.","Combined oxybate revenue (incl. AG royalties) $491.8M (-2% YoY); Xyrem down 41% to $159.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":2.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":1850129000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292742,"accession_number":"0001193125-23-172528","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2023-06-22T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Jazz Pharmaceuticals files lawsuit challenging FDA approval of Lumryz","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Filed complaint in U.S. District Court for DC seeking to vacate FDA's May 1, 2023 approval of Lumryz NDA.","Alleges FDA acted outside Orphan Drug Act by granting Lumryz ODE despite Xywav's unexpired exclusivity.","Claims FDA's finding of clinical superiority (once-nightly dosing) lacks substantial evidence and is inconsistent with prior determinations.","Seeks declaration that approval was arbitrary, capricious, and in excess of statutory authority.","Jazz cannot predict outcome or impact on oxybate business."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292741,"accession_number":"0001232524-23-000025","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jazz Q1 EPS $1.04, adj. $3.95; rev $893M (+10%); Xywav +49%, guidance affirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $69.4M ($1.04 EPS) vs $1.6M ($0.03) in 1Q22; non-GAAP adj. net income $285.3M ($3.95 EPS) vs $261.9M ($3.73).","Total revenue $892.8M (+10% YoY); neuroscience $654.0M (+7%), oncology $228.9M (+16%).","Xywav net sales $277.8M (+49%), Epidiolex $188.9M (+20%), Rylaze $85.9M (+58%).","FY 2023 guidance affirmed: rev $3.675-3.875B; GAAP EPS $5.90-$7.90; non-GAAP adj. EPS $16.90-$17.85.","Pipeline: zanidatamab ASCO June 2, JZP150 PTSD Phase 2 top-line late 2023, suvecaltamide ET Phase 2b 1H24."],"consensus_eps_estimate":null,"consensus_eps_actual":1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":892812000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313385,"accession_number":"0001232524-23-000014","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2023-03-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jazz Pharma reports record 2022 revenue of $3.7B, up 18% YoY; guides 2023 revenue $3.675-3.875B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record 2022 total revenue $3.7B (+18% YoY); 2023 revenue guidance $3.675-3.875B (3% growth at midpoint).","Xywav became largest product in Q4, annualizing >$1B; more narcolepsy patients on Xywav than Xyrem.","Cash from operations $1.3B in 2022; delevered balance sheet to 2.9x adjusted net leverage.","Pipeline progress: positive zanidatamab pivotal trial in BTC; Phase 2 suvecaltamide in Parkinson's tremor enrolled.","FDA approved Rylaze sBLA for MWF IM dosing; Epidyolex launched in all five key EU markets."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":3659374000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313384,"accession_number":"0001193125-23-004151","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jazz Pharma reaffirms FY2022 revenue guidance at J.P. Morgan conference","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Company expects to meet previously announced total, neuroscience and oncology revenue guidance for FY2022.","Presentation includes corporate overview and financial update; no change to existing guidance ranges.","No specific revenue or earnings figures disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313383,"accession_number":"0001193125-23-001607","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2023-01-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Jazz Pharmaceuticals sues 10 generic filers over Epidiolex patents; seeks 30-month stay","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["10 ANDA filers, including Teva, Padagis, Apotex, Lupin, Taro, and others, filed paragraph IV certifications for generic Epidiolex.","Jazz filed patent infringement suit on January 3, 2023 in District of New Jersey.","Lawsuit seeks FDA approval no earlier than expiration of last asserted patent; triggers automatic 30-month stay.","Epidiolex has Orphan Drug Exclusivity for LGS/Dravet through Sept 2025 (ages 2+) and July 2027 (ages 1-2 and TSC).","No other ANDA filers identified as of filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331908,"accession_number":"0001193125-22-309581","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2022-12-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Jazz exercises zanidatamab option; pays $325M; 41.3% ORR in BTC trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Jazz exercised option to retain exclusive rights to zanidatamab in U.S., Europe, and Japan.","One-time $325M payment in Q4 2022; total potential milestones up to $1.76B plus royalties.","Pivotal HERIZON-BTC-01 trial showed 41.3% ORR (95% CI: 30.4-52.8) and median DOR 12.9 months.","Safety profile consistent with prior monotherapy; no new safety signals.","Zymeworks eligible for tiered royalties of 10-20% on Jazz net sales pending approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331907,"accession_number":"0001193125-22-298441","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2022-12-05T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Jazz acquires exclusive zanidatamab rights from Zymeworks for $50M upfront","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront $50M non-refundable cash payment; potential $325M payment after HERIZON-BTC-01 top-line data.","Regulatory milestones up to $525M; commercial milestones up to $862.5M.","Tiered royalties of 10%-20% on annual net sales in the Territory.","Exclusive rights in U.S., Europe, Japan; Asia/Pacific territories excluded per prior BeiGene license.","Agreement effective Nov 29, 2022 following HSR clearance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331906,"accession_number":"0001193125-22-284671","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Jazz completes ex-U.S. divestiture of Sunosi to Axsome","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Completed ex-U.S. divestiture of Sunosi (solriamfetol) to Axsome Therapeutics on November 14, 2022.","Earlier U.S. divestiture of Sunosi completed on May 9, 2022.","Original deal announced on March 28, 2022; global divestiture now fully completed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331905,"accession_number":"0001232524-22-000045","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jazz Pharma Q3 revenue $940.7M (+12% YoY); raises FY guidance mid-point to $3.65B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total revenue $940.7M, up 12% YoY; driven by Xywav, Epidiolex, and Rylaze demand.","Raises 2022 total revenue guidance mid-point to $3.65B, up from prior range.","Operating cash flow YTD $930M; cash $899.4M; net leverage ratio 2.9x.","More narcolepsy patients now on Xywav than Xyrem as of October 2022 milestone.","Pipeline progress: first patients enrolled in Phase 1 JZP815 and Phase 3 Epidyolex in Japan."],"consensus_eps_estimate":null,"consensus_eps_actual":0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":2687251000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331904,"accession_number":"0001193125-22-264875","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2022-10-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Jazz licenses zanidatamab from Zymeworks for up to $1.76B; $50M upfront, $325M option payment","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Exclusive rights in U.S., Europe, Japan for HER2-targeted bispecific antibody zanidatamab.","Zymeworks eligible for $50M upfront, $325M option payment after HERIZON-BTC-01 data, plus up to $1.39B milestones.","Tiered royalties of 10%-20% on net sales; deal expected to close in 2022 subject to HSR clearance.","Zanidatamab in pivotal trials for biliary tract cancer and gastroesophageal adenocarcinoma.","FDA Breakthrough Therapy and Fast Track designations; top-line BTC data expected by end of 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349374,"accession_number":"0001232524-22-000034","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2022-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jazz Pharma Q2 revenue $932.9M (+24% YoY), affirms FY2022 guidance, net leverage target met early","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2022 total revenues $932.9M, up 24% YoY; strong commercial execution across franchises.","2022 total revenue guidance affirmed at $3.5-3.7B; GAAP guidance updated for FX movements.","Net leverage ratio 3.2x, achieving target six months ahead of schedule, providing balance sheet flexibility.","Milestones: more patients on Xywav than Xyrem; JZP458 MAA submitted to EMA; JZP815 IND cleared by FDA.","Divested Sunosi to sharpen focus on strategic priorities; pipeline expanded with JZP441 and JZP898."],"consensus_eps_estimate":null,"consensus_eps_actual":0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":1746599000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-08-03T23:59:59+00:00|349374"}